BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Cock RF, Smits A, Allegaert K, de Hoon J, Saegeman V, Danhof M, Knibbe CA. Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates. J Antimicrob Chemother 2014;69:1330-8. [PMID: 24492261 DOI: 10.1093/jac/dkt527] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Zachariah P, Saiman L. Expanding antimicrobial stewardship strategies for the NICU: Management of surgical site infections, perioperative prophylaxis, and culture negative sepsis. Seminars in Perinatology 2020;44:151327. [DOI: 10.1016/j.semperi.2020.151327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Palma EC, Meinhardt NG, Stein AT, Heineck I, Fischer MI, de Araújo B, Dalla Costa T. Efficacious Cefazolin Prophylactic Dose for Morbidly Obese Women Undergoing Bariatric Surgery Based on Evidence from Subcutaneous Microdialysis and Populational Pharmacokinetic Modeling. Pharm Res 2018;35. [DOI: 10.1007/s11095-018-2394-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 De Cock PAJG, Mulla H, Desmet S, De Somer F, Mcwhinney BC, Ungerer JPJ, Moerman A, Commeyne S, Vande Walle J, Francois K, Van Hasselt JGC, De Paepe P. Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass to optimize dosing regimens for children undergoing cardiac surgery. J Antimicrob Chemother . [DOI: 10.1093/jac/dkw496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
4 Asada M, Nagata M, Mizuno T, Uchida T, Takahashi H, Makita K, Arai H, Kijima S, Echizen H, Yasuhara M. Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass in adult patients undergoing cardiac surgery. Eur J Clin Pharmacol 2021;77:735-45. [PMID: 33211137 DOI: 10.1007/s00228-020-03045-1] [Reference Citation Analysis]
5 Hartman SJF, Upadhyay PJ, Hagedoorn NN, Mathôt RAA, Moll HA, van der Flier M, Schreuder MF, Brüggemann RJ, Knibbe CA, de Wildt SN. Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study. Clin Pharmacokinet 2021. [PMID: 34036552 DOI: 10.1007/s40262-021-01035-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Allegaert K, van den Anker J. Neonates are not just little children and need more finesse in dosing of antibiotics. Acta Clin Belg 2019;74:157-63. [PMID: 29745792 DOI: 10.1080/17843286.2018.1473094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Lantinga MA, Wijnands TF, Te Morsche RH, de Sévaux RG, Kuipers S, Allegaert K, Burger D, Drenth JP. Hepatic cyst penetration of cefazolin in patients receiving aspiration sclerotherapy. J Antimicrob Chemother 2016;71:2547-52. [PMID: 27246239 DOI: 10.1093/jac/dkw172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Elkayal O, Allegaert K, Spriet I, Smits A, Seghaye MC, Charlier C, Dreesen E. Population pharmacokinetics of cefazolin in maternal and umbilical cord plasma, and simulated exposure in term neonates. J Antimicrob Chemother 2021:dkab329. [PMID: 34499720 DOI: 10.1093/jac/dkab329] [Reference Citation Analysis]
9 Salvador E, Oualha M, Bille E, Beranger A, Moulin F, Benaboud S, Boujaafar S, Gana I, Urien S, Zheng Y, Toubiana J, Briand C, Bustarret O, Geslain G, Renolleau S, Treluyer JM, Hirt D. Population pharmacokinetics of cefazolin in critically ill children infected with methicillin-sensitive Staphylococcus aureus. Clin Microbiol Infect 2021;27:413-9. [PMID: 32360445 DOI: 10.1016/j.cmi.2020.04.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Wilbaux M, Fuchs A, Samardzic J, Rodieux F, Csajka C, Allegaert K, van den Anker JN, Pfister M. Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates. J Clin Pharmacol 2016;56:909-35. [PMID: 26766774 DOI: 10.1002/jcph.705] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
11 Crutchfield CA, Marzinke MA. Bioanalytical development and validation of liquid chromatographic-tandem mass spectrometric methods for the quantification of total and free cefazolin in human plasma and cord blood. Pract Lab Med 2015;1:12-21. [PMID: 28932794 DOI: 10.1016/j.plabm.2015.03.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
12 Standing JF, Ongas MO, Ogwang C, Kagwanja N, Murunga S, Mwaringa S, Ali R, Mturi N, Timbwa M, Manyasi C, Mwalekwa L, Bandika VL, Ogutu B, Waichungo J, Kipper K, Berkley JA; FLACSAM-PK Study Group. Dosing of Ceftriaxone and Metronidazole for Children With Severe Acute Malnutrition. Clin Pharmacol Ther 2018;104:1165-74. [PMID: 29574688 DOI: 10.1002/cpt.1078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
13 Marr I, Swe K, Henderson A, Lacey JA, Carter GP, Ferguson JK. Cefazolin susceptibility of coagulase-negative staphylococci (CoNS) causing late-onset neonatal bacteraemia. J Antimicrob Chemother 2021:dkab402. [PMID: 34791307 DOI: 10.1093/jac/dkab402] [Reference Citation Analysis]
14 Keij FM, Achten NB, Tramper-Stranders GA, Allegaert K, van Rossum AMC, Reiss IKM, Kornelisse RF. Stratified Management for Bacterial Infections in Late Preterm and Term Neonates: Current Strategies and Future Opportunities Toward Precision Medicine. Front Pediatr 2021;9:590969. [PMID: 33869108 DOI: 10.3389/fped.2021.590969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Allegaert K. Tailored tools to improve pharmacotherapy in infants. Expert Opin Drug Metab Toxicol 2014;10:1069-78. [PMID: 24961300 DOI: 10.1517/17425255.2014.931937] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
16 van den Anker J, Allegaert K. Rational Use of Antibiotics in Neonates: Still in Search of Tailored Tools. Healthcare (Basel) 2019;7:E28. [PMID: 30781454 DOI: 10.3390/healthcare7010028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
17 Smits A, De Cock P, Vermeulen A, Allegaert K. Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute. Expert Opin Drug Metab Toxicol 2019;15:25-34. [PMID: 30554542 DOI: 10.1080/17425255.2019.1558205] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
18 Völler S, Flint RB, Stolk LM, Degraeuwe PLJ, Simons SHP, Pokorna P, Burger DM, de Groot R, Tibboel D, Knibbe CAJ; DINO study group. Model-based clinical dose optimization for phenobarbital in neonates: An illustration of the importance of data sharing and external validation. Eur J Pharm Sci 2017;109S:S90-7. [PMID: 28506869 DOI: 10.1016/j.ejps.2017.05.026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
19 Abduljalil K, Pan X, Pansari A, Jamei M, Johnson TN. A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model Building. Clin Pharmacokinet 2020;59:485-500. [PMID: 31583613 DOI: 10.1007/s40262-019-00825-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
20 Cristea S, Krekels EHJ, Allegaert K, De Paepe P, de Jaeger A, De Cock P, Knibbe CAJ. Estimation of Ontogeny Functions for Renal Transporters Using a Combined Population Pharmacokinetic and Physiology-Based Pharmacokinetic Approach: Application to OAT1,3. AAPS J 2021;23:65. [PMID: 33948771 DOI: 10.1208/s12248-021-00595-9] [Reference Citation Analysis]
21 Balevic SJ, Smith PB, Testoni D, Wu H, Brouwer KLR, Zimmerman KO, Rivera-Chaparro ND, Benjamin DK Jr, Cohen-Wolkowiez M. Cefazolin pharmacokinetics in premature infants. J Perinatol 2019;39:1213-8. [PMID: 30944398 DOI: 10.1038/s41372-019-0368-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Ongas M, Standing J, Ogutu B, Waichungo J, Berkley JA, Kipper K. Liquid chromatography-tandem mass spectrometry for the simultaneous quantitation of ceftriaxone, metronidazole and hydroxymetronidazole in plasma from seriously ill, severely malnourished children. Wellcome Open Res 2017;2:43. [PMID: 29479566 DOI: 10.12688/wellcomeopenres.11728.2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
23 Mcwilliam SJ, Hawcutt DB. Solving the problem of dose optimization of children’s medicines. Expert Review of Clinical Pharmacology 2018;11:205-8. [DOI: 10.1080/17512433.2018.1431528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Ongas M, Standing J, Ogutu B, Waichungo J, Berkley JA, Kipper K. Liquid chromatography-tandem mass spectrometry for the simultaneous quantitation of ceftriaxone, metronidazole and hydroxymetronidazole in plasma from seriously ill, severely malnourished children. Wellcome Open Res 2017;2:43. [PMID: 29479566 DOI: 10.12688/wellcomeopenres.11728.2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]